Zhiqiang Meng

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

Zhenggang Ren, Jianming Xu, Yuxian Bai et al. · The Lancet Oncology · 2021 · 1K citations

Hepatology, Bevacizumab Biosimilar, Medicine +8

A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy

Qi Qi, Liping Zhuang, Yehua Shen et al. · Cancer · 2016 · 641 citations · Full text

Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial

Shukui Qin, Zhenggang Ren, Zhiqiang Meng et al. · The Lancet Oncology · 2020 · 625 citations

Hepatology, Medicine, Pathology +6

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study

Shukui Qin, Stephen L. Chan, Shanzhi Gu et al. · The Lancet · 2023 · 590 citations

First-line Therapy, Hepatology, International Phase 3 +8

Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)

Jian Zhou, Hui‐Chuan Sun, Zheng Wang et al. · Liver Cancer · 2023 · 389 citations · Full text